Oncology for the Inquisitive Mind
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for more information.
Show episodes
This week, we talk about metastatic bladder cancer. The last two years have seen drastic changes in this space, with the addition of immunotherapy and ADCs in a first-line setting. While exceptionally effective, toxicity and patient selection remain challenging. The other big issue with what's best for the second line?
This week, we explore muscle-invasive bladder cancer (MIBC). This space has made significant progress with the completion of two pivotal trials. The first was VESPER, comparing two chemotherapy regimens. The key to this trial may be the amount of cisplatin delivered, but there are some unknowns in a real-world setting.
156. Back to Basics - Prostate Cancer - Biochemical Recurrence and Oligometastatic Disease Control
As we "EMBARK" on our next Prostate Cancer adventure via the "SOLAR" system to "SATURN," Michael and Josh explore the idea of biochemical recurrence in prostate cancer and the role of radiotherapy in tumour-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer. Both excellent studies r
Marie Curie's life work laid the foundations for theranostics. This week, we talk about Lutetium, a rare earth metal, and its role in Prostate Cancer. Lutetium-177 PSMA therapy is a radiation therapy that targets prostate cancer. It is used in the advanced, metastatic, and castrate-resistant space. Lutetium is bound to
154. Back to Basics - Non Metastatic and Metastatic Prostate Cancer - The Journey Continues
Prostate Cancer has a multitude of presentations, but when metastatic, it usually spreads directly to the lymph nodes or the bones. This episode focuses on the contentious definition of "M0 Castrate Resistant Prostate Cancer (CRPC)", also known as Nonmetastatic CRPC. Does this definition exist, and what role will PSMA
This week, we interview Dr. Cristofanilli, a globally recognised expert in inflammatory breast cancer research and precision medicine. With decades of clinical experience and groundbreaking contributions to translational research, he has transformed the way we approach metastatic breast cancer, leading advances in liqu